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Background: Although chronic obstructive pulmonary disease (COPD) is a major global health burden there is a
lack of patient awareness of disease severity, particularly in relation to exacerbations.
Methods: We conducted a global patient survey using an innovative, internet-based methodology to gain insight
into patient perceptions of COPD and exacerbations in a real-world sample typical of today’s working-age COPD
population.
Results: Two thousand patients with COPD (53%), chronic bronchitis (52%) and/or emphysema (22%) from 14
countries completed an online questionnaire developed by the authors. The Medical Research Council (MRC)
breathlessness scale was used to delineate symptom severity. Over three quarters of patients (77%) had experienced an
exacerbation, with 27% of MRC 1 and 2 patients and 52% of MRC 3, 4 and 5 patients requiring hospitalization as a
result of an exacerbation. While a majority of MRC 1 and 2 patients (51%) reported being back to normal within a few
days of an exacerbation, 23% of MRC 3, 4 and 5 patients took several weeks to return to normal and 6% never fully
recovered. A high proportion of patients (39%) took a ‘wait and see’ approach to exacerbations.
Despite the high prevalence of exacerbations and their negative impact on quality of life, 73% of MRC 1 and 2 patients
and 64% of MRC 3, 4 and 5 patients felt that they had control of their COPD. However, 77% of all patients were worried
about their long-term health, and 38% of MRC 1 and 2 patients and 59% of MRC 3, 4 and 5 patients feared premature
death due to COPD.
Conclusions: To reduce the adverse effects of COPD on patients’ quality of life and address their fears for the future,
we need better patient education and improved prevention and treatment of exacerbations.
Keywords: COPD, Exacerbation, Patient-reported, SurveyBackground
Chronic obstructive pulmonary disease (COPD) is a
major global health burden in both developed and devel-
oping countries. The disease is predicted to become the
third leading cause of worldwide disease burden by 2030
[1]. COPD is also the leading respiratory cause of days
lost from work [2], and three quarters of COPD patients
report difficulty in simple day-to-day activities such as
dressing and walking up stairs [3].* Correspondence: neil.barnes@bartshealth.nhs.uk
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reproduction in any medium, provided the orUntil recently, the major goal of COPD treatment was
the reduction of symptoms. However, with the recogni-
tion that exacerbations of COPD are very common, have
a major adverse impact on quality of life, and may speed
disease progression, guidelines and clinical attention are
focusing on reducing future risks, such as the prevention
and treatment of exacerbations [4]. In developed coun-
tries the hospitalization of COPD patients, caused pre-
dominantly by exacerbations, accounts for more than
50% of direct healthcare costs [5].
Surveys of patients with COPD have found that there
is a considerable burden of disease and that patients
have a poor knowledge of COPD [6-9]. Furthermore, an
international survey of 3,265 COPD patients revealed thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[10]. However, these surveys have relied on relatively small
sample sizes or have been predominantly focused on
Europe and North America. Therefore, we aimed to gain
a global insight into patients’ perceptions of COPD and,
more uniquely, their exacerbations, in a real-world set-
ting using an innovative, internet-based methodology.
The survey was designed to identify differences and
similarities in perceptions between patients of differing
COPD severities, using the Medical Research Council
(MRC) breathlessness scale to delineate severity [11].Figure 1 Flow diagram of patient selection.Methods
The survey was performed in 14 countries: Australia,
Brazil, Canada, China, Denmark, France, Germany, Italy,
the Netherlands, Poland, South Korea, Spain, Turkey
and the UK. These countries were chosen to provide a
wide geographic and economic spread.
An online approach was used to ensure that the meth-
odology was globally consistent while avoiding the need
to rely on treatment centres for recruitment and taking
into account the difficulty in implementing a telephone
survey in countries such as China and Brazil. The survey
therefore avoided potential biases within specialist cen-
tres or regions as well as biases related to disease sever-
ity or treatment. This innovative, internet-based method,
commonly used for consumer research, recruited partici-
pants from established online general population re-
search panels containing over 18 million members
worldwide. The research was implemented by profes-
sional market researchers (ICM Research) in accordance
with the Legal and Ethical Guidelines issued by the British
Healthcare Business Intelligence Association (BHBIA) and
was conducted in accordance with codes of conduct re-
garding anonymity, confidentiality and ethical practice.
The survey was therefore exempt from ethics approval
under the UK Governance arrangements for research eth-
ics committees.
Based on a self-reported respiratory condition/breath-
ing problem and/or a positive current or former smoking
history, 255,710 individuals were invited to participate in
the survey between 09 July and 02 September 2010. Infor-
mation about the survey, which included the length of
time for completion of the questionnaire (approximately
17 minutes), was e-mailed to the invitees. Incentives were
offered in line with the terms and conditions of the
panels, and were often non-monetary, or ranged from the
equivalent of £0.20 to £1 per minute of survey. Of
255,710 invitees, 75,233 responded and, after providing
consent, were screened for eligibility, producing 5,929 re-
spondents who were able to withdraw at any point. A
sample size of 2,000 completed questionnaires was used
for analysis (Figure 1).All patients who took part needed to have been diag-
nosed by a clinician with one or more of the following
conditions: COPD, chronic bronchitis or emphysema.
Patients also needed to have at least two of the following
symptoms: breathlessness on exertion, mucus/sputum/
phlegm production, chronic or troublesome cough, chest
pain when walking, regular chest infections (especially in
the winter) or leg pain when walking. Disease severity
was measured by asking patients to assess themselves
according to the criteria of the MRC breathlessness
scale (Grades 1–5) [11]. A symptom-based definition of
exacerbations was used (a worsening of at least one
symptom of COPD lasting for at least 48 hours) [12],
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relevant question.
The survey consisted of a two-part, online, self-
completion questionnaire that used an adaptive question
approach to minimize unnecessary questions and shorten
completion times. The questions were developed by the
authors using standard measures where appropriate (for
example, the MRC breathlessness scale). The question-
naire and the screening approach can be viewed in the on-
line supplement.
The survey was tested by three individuals prior to
launch, and was then ‘soft-launched’ to a limited number
of respondents (50–100 per country) so that the data
and survey mechanism could be tested for sense/logic,
and the average time for completion checked against the
original estimate. As some questions were open-ended,
completed questionnaires could contain unanswered
questions, and checks were only made to ascertain
whether text was entered. In addition, respondents were
offered a “don’t know” answer where applicable to avoid
forcing inaccurate responses. Data from incomplete
questionnaires were collected but not processed or
analysed.
No analytical time stamps were used but all data were
logic tested to ensure that respondents did not provide
contradictory answers. Quality control questions were
included at the beginning and end of the questionnaire.
These asked personal information, for example, age at
the beginning of the questionnaire and date of birth at
the end, and if these answers did not match, the respon-
dent’s questionnaire was rejected.
Data were stored in compliance with the UK Data Pro-
tection Act (1998) on secure servers that could be
accessed only by relevant researchers, and each respond-
ent was issued with a unique Uniform Resource Locator
(URL) that could be used once to access the question-
naire. Respondents were not able to review or edit their
answers to previous questions.
The current publication was developed in line with the
Checklist for Reporting Results of Internet E-Surveys
(CHERRIES) [13].
Statistical analysis
The collected data were processed and tabulated into
electronic data tables. Descriptive statistics are presented
herein.
Role of the funding source
The study was sponsored by Nycomed (a Takeda com-
pany). A Steering Committee of COPD experts including
primary and secondary care physicians designed the sur-
vey in conjunction with six representatives of the spon-
sor. This included the original study design and concept,
the plan for the analyses, full access to the data andresponsibility for decisions with regard to publication.
The research was implemented by professional market
researchers (ICM Research).
Results
The 2,000 completed questionnaires consisted of 150
questionnaires from each country except for Denmark
and Turkey, where limited numbers of individuals in
consumer research panels meant that only 100 com-
pleted questionnaires in each of these countries were
gathered. The mean age (standard error [SE]) of the
population was 52.99 (0.22) years, 53% of patients were
current smokers, 1,231 (62%) patients were classified as
MRC breathlessness scale 1 and 2, and 769 (38%) pa-
tients were classified as MRC breathlessness scale 3, 4
and 5 (Table 1). The UK had the highest percentage
(58%) and Italy the lowest percentage (22%) of MRC 3, 4
and 5 patients (Table 1). Symptoms such as breathless-
ness on exertion, fatigue, sputum production and cough
were very common (Table 1). Regular chest infections
were experienced by 41% of MRC 1 and 2 patients and
57% of MRC 3, 4 and 5 patients. The majority of pa-
tients (69%) thought that their COPD was controlled,
yet MRC 1 and 2 patients and MRC 3, 4 and 5 patients
reported a mean (SE) of 10 (0.27) and 18 (0.37) days per
month, respectively, in which COPD negatively affected
their life. The majority of patients felt that their doctor
took their disease seriously or very seriously, with only a
minority (5% of all patients) feeling that their doctor did
not take their condition seriously at all (Table 1).
Patients reported high healthcare utilization in the
preceding 12 months of the survey (Figure 2). This
included high frequencies of scheduled and unsched-
uled visits to primary care physicians, specialists and
allied healthcare professionals such as physiotherapists
(Figure 2). Use of unscheduled healthcare was particu-
larly common among MRC 3, 4 and 5 patients, with a per-
year mean (SE) of 1.77 (0.17) unscheduled GP visits, 0.85
(0.13) unscheduled visits to hospital specialists and 0.70
(0.11) unscheduled visits to a nurse. MRC 3, 4 and 5 pa-
tients also reported a per-year mean (SE) of 1.06 (0.12) un-
scheduled visits to the emergency department, with 19%
of these patients reporting two or more visits.
Self-reported comorbidities were generally more com-
mon in MRC 3, 4 and 5 patients compared with MRC 1
and 2 patients, and included hypertension (37%), anxiety
(36%), depression (34%), leg muscle weakness (30%),
heartburn (29%), arthritis (28%), hyperlipidaemia/high
cholesterol (22%), sleep apnoea (23%) and diabetes (20%)
(Figure 3).
Prescription medication was used by a high percentage
of all patients (89%), with bronchodilators the mainstay
of treatment, as per COPD guidelines (Table 2) [4]. Over
a quarter (27%) of patients had taken steroids, and 43%





N (%) 1,231 (62%) 769 (38%)
Male, n (%) 656 (53%) 392 (51%)
Female, n (%) 575 (47%) 377 (49%)
Mean age, years (SE) 52.03 (0.28) 54.54 (0.35)
MRC breathlessness scale by country, n (%)*
Australia 84 (56%) 66 (44%)
Brazil 106 (71%) 44 (29%)
Canada 70 (47%) 80 (53%)
China 110 (73%) 40 (27%)
Denmark 50 (50%) 50 (50%)
France 79 (53%) 71 (47%)
Germany 84 (56%) 66 (44%)
Italy 113 (75%) 37 (25%)
The Netherlands 94 (63%) 56 (37%)
Poland 98 (65%) 52 (35%)
South Korea 101 (67%) 49 (33%)
Spain 107 (71%) 43 (29%)
Turkey 72 (72%) 28 (28%)
The UK 63 (42%) 87 (58%)
Have you ever taken a pulmonary
function test? n (%)
Yes 960 (78%) 678 (88%)
No 223 (18%) 64 (8%)
Current smoking behaviour
More than 20 cigarettes per day, n (%) 136 (11%) 91 (12%)
Up to 20 cigarettes per day, n (%) 536 (44%) 295 (38%)
Former smoker, n (%) 396 (32%) 307 (40%)
Never smoked, n (%) 163 (13%) 76 (10%)
Days negatively affected by COPD
in a 30 day month, mean days (SE)
10 (0.27) 18 (0.37)
COPD symptoms experienced, n (%)
Breathlessness on exertion 958 (78%) 704 (92%)
Fatigue 752 (61%) 606 (79%)
Mucus/sputum/phlegm production 731 (59%) 505 (66%)
Chronic/troublesome cough 729 (59%) 484 (63%)
Regular chest infections especially in winter 500 (41%) 439 (57%)
Leg pain on walking 331 (27%) 340 (44%)
Chest pain on walking 218 (18%) 277 (36%)
Other 24 (2%) 15 (2%)
How seriously does your doctor
take your COPD? n (%)
Very seriously 297 (24%) 331 (43%)
Fairly seriously 480 (39%) 303 (39%)
Not particularly seriously 347 (28%) 107 (14%)
Not at all seriously 51 (4%) 11 (1%)
Table 1 Patient demographics, symptoms and perceptions
(Continued)
How well do patients think their
COPD is controlled? n (%)
Not at all well 47 (4%) 54 (7%)
Not particularly well 255 (21%) 204 (27%)
Quite well 718 (58%) 443 (58%)
Very well 178 (14%) 51 (7%)
MRC=Medical Research Council breathlessness scale; SE=standard error;
COPD=chronic obstructive pulmonary disease.
*N=150 for each country except for Denmark and Turkey where N=100.
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of MRC 3, 4 and 5 patients had taken oxygen. Patients
commonly increased medication use with worsening
symptoms (Table 2). Lifestyle choices for managing
COPD, such as quitting smoking, exercising and eating
more healthily, were also common (Table 2).
Over three quarters (77%) of all patients had experi-
enced an exacerbation (Table 3). The proportion of pa-
tients reporting exacerbations in the preceding year was
also high: 62% and 80% for MRC 1 and 2 patients and
MRC 3, 4 and 5 patients, respectively. A high percentage
of patients had had two or more exacerbations in the
preceding 12 months (Figure 4). Over a half (53%) of
MRC 3, 4 and 5 patients had experienced an exacerba-
tion that required hospitalization (Table 3). While a ma-
jority of MRC 1 and 2 patients (51%) reported being
back to normal within a few days of an exacerbation,
23% of MRC 3, 4 and 5 patients took several weeks to
return to normal and 6% never fully recovered. A high
proportion of patients (39%) took a ‘wait and see’ ap-
proach to exacerbations (Table 3).
Nearly three quarters (73%) of patients contacted their
healthcare service during an exacerbation (Figure 5).
Other patient reactions to an exacerbation included rest,
cutting down on smoking, taking higher doses of medi-
cation and taking a medication that would not be part of
their usual regimen (Figure 5). Common reasons for
seeking healthcare during an exacerbation were an in-
crease in breathlessness, symptoms not improving suffi-
ciently and ineffective medication (Figure 6).
Patients felt that COPD and exacerbations affected
their quality of life and the ability to commit to future
events (Figure 7). Over three quarters (77%) of all pa-
tients were worried about their long-term health, and
38% of MRC 1 and 2 patients and 59% of MRC 3, 4 and 5
patients feared premature death due to COPD (Table 3).
Discussion
Our survey provides a unique, global perspective of how
COPD patients perceive their illness and its impact on
their everyday lives, with a focus on patient attitudes
Figure 2 Healthcare utilization in the preceding 12 months.
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research panels aimed to identify ‘real-world’ COPD pa-
tients whose views and experiences of the condition
were typical of a wider COPD population. Online re-
cruitment had the advantage of assessing a wide cross-
section of the population but had the disadvantage of
only assessing individuals with access to the internet
who were motivated to respond. Therefore, the data
herein may under-represent older individuals and over-
represent more symptomatic individuals who were moti-
vated to respond. However, the age, gender balance,
smoking prevalence, symptom reporting, comorbidities
and treatment history of the group suggest that respon-
dents were indeed a representative COPD population.
With a mean age of 53 years, the survey cohort was
already experiencing regular exacerbations, a consider-
able impact on daily functioning and high levels of
healthcare utilization. These findings support those of
other studies that show that the impact of COPD is
not restricted to an elderly population [8,14,15]. In-
deed, an analysis of data from the European CommunityRespiratory Health Survey of over 18,000 adults aged
20–44 years concluded that a considerable percentage
of the population showed signs of COPD (11.8% GOLD
stage 0, 2.5% GOLD stage 1 and 1.1% GOLD stages 2
and 3) [15].
The incidence of comorbidities reported here is likely
associated with the age and smoking characteristics of
the population – over half of patients in our survey were
current smokers. Comorbidities were common, and were
generally similar to those reported by another survey of
patients with COPD [9], the Evaluation of COPD Longi-
tudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE) data [16], and the comorbidities of COPD pa-
tients in The Health Improvement Network (THIN)
database [17]. However, the rates of comorbidities in our
survey were generally lower than those reported by other
studies [9,16,17]. Furthermore, rates of comorbidities
were generally higher in MRC 3, 4, and 5 patients com-
pared with MRC 1 and 2 patients in our survey, con-
trasting with the ECLIPSE study that reported no
relationship between comorbidity prevalence and COPD
Figure 3 Comorbidities.
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compared with the other studies, and inclusion of patients
with chronic bronchitis and/or emphysema in our survey,
may explain the differing comorbidity observations.
Treatment history was typical of a COPD population,
and showed a relatively positive infiltration of guideline
messages and an encouraging level of physical manage-
ment approaches. The COPD Resource Network Needs
Assessment Survey reported both patient and physician
confusion about COPD treatment choices, and under-
use of pulmonary rehabilitation [6]. In our survey, pa-
tients reported using physical and breathing exercises,
but low rates of pulmonary rehabilitation, suggesting
that better access to this treatment approach is still
needed.
Patients generally believed that their COPD was well
controlled despite the high rate of exacerbations and
resulting need to consult healthcare services, rest and in-
crease their medication. This type of mismatch is not
unusual, and has been widely reported in studies of both
COPD and asthma patients, suggesting low levels of ex-
pectation [6,10,18]. For example, the Confronting COPD
International Survey, the first large international (EU
and US) survey on the burden of COPD, reported that
over a third of patients with the most severe breathless-
ness (too breathless to leave the house) described their
condition as mild or moderate, as did 60% of patientscharacterised as breathless after walking a few minutes
on level ground [10]. Similarly, in the COPD Resource
Network Needs Assessment Survey, the majority of pa-
tients expressed satisfaction with their care despite ex-
periencing significant symptoms and high healthcare
utilization [6].
The MRC breathlessness scale proved a useful self-
assessment indicator of COPD severity in our survey,
with a consistent association between higher MRC scale
(3, 4 and 5) and increased prevalence of exacerbations
and symptoms, increased prescribed medication use and
greater healthcare utilization. In addition, nearly twice as
many MRC 3, 4 and 5 patients reported that their doctor
took their condition very seriously compared with MRC
1 and 2 patients.
Patient reporting of COPD exacerbations is a relatively
reliable measure of true exacerbation frequency, with a
good correlation between patient recall of the number of
exacerbations and documented occurrence of exacerba-
tions [19,20]. Furthermore, the high prevalence of exac-
erbations reported in our survey is consistent with those
in other studies of COPD patient reports [7,20-22]. For
example, in the Perception of Exacerbations of Chronic
Obstructive Pulmonary Disease (PERCEIVE) survey,
89% of patients reported at least one episode of ‘flare-
up’ of symptoms during the preceding year [7]. Patient-
reported exacerbation rates are typically higher than
Table 2 Treatments and lifestyle choices for
managing COPD
MRC 1 and 2 MRC 3, 4 and 5
(n=1,231) (n=769)
Treatments and lifestyle choices for managing
COPD, n (%)
Long-acting bronchodilators 710 (58%) 582 (76%)
Short-acting bronchodilators 390 (32%) 406 (53%)
Antibiotics 494 (40%) 358 (47%)
Steroids (all types) 267 (22%) 273 (36%)
Other prescription medication 179 (15%) 168 (22%)
Natural remedies and/or
alternative medicine
232 (19%) 147 (19%)
Quit smoking 509 (41%) 365 (47%)
Cutting down on smoking 480 (39%) 286 (37%)
Breathing exercise 405 (33%) 367 (48%)
Eating healthier/better diet 445 (36%) 320 (42%)
Physical exercise 455 (37%) 251 (33%)
Oxygen 119 (10%) 176 (23%)
Pulmonary rehabilitation 87 (7%) 136 (18%)
Treatments and lifestyle choices used more by
patients during COPD symptom worsening, n (%)
Long-acting bronchodilators 854 (69%) 522 (68%)
Short-acting bronchodilators 339 (28%) 294 (38%)
Antibiotics 228 (19%) 179 (23%)
Steroids (all types) 202 (16%) 168 (22%)
Other prescription medication 118 (10%) 85 (11%)
Natural remedies and/or
alternative medicine
187 (15%) 95 (12%)
Quit smoking 182 (15%) 104 (14%)
Cutting down on smoking 278 (23%) 150 (20%)
Breathing exercise 273 (22%) 205 (27%)
Eating healthier/better diet 203 (16%) 126 (16%)
Physical exercise 217 (18%) 113 (15%)
Oxygen 170 (14%) 133 (17%)
Pulmonary rehabilitation 118 (10%) 82 (11%)
MRC=Medical Research Council breathlessness scale; COPD=chronic obstructive
pulmonary disease.






Proportion of patients with an exacerbation, n (%)
Ever 875 (71%) 659 (86%)
In the last 12 months 760 (62%) 617 (80%)
Proportion of people hospitalised by an
exacerbation (baseline: n=875 & 659), n (%)
239 (27%) 342 (52%)
Time taken to return to normal after an
exacerbation (baseline: n=875 & 659), n (%)
Within a few days 450 (51%) 266 (40%)
Within a week 255 (29%) 169 (26%)
Within a few weeks 104 (12%) 150 (23%)
Within a month 28 (3%) 18 (3%)
Within a few months 16 (2%) 14 (2%)
Longer 7 (1%) 3 (0%)
Never 15 (2%) 39 (6%)
Patient reaction to the onset of an
exacerbation (baseline: n=875 & 659), n (%)
Take action right away 493 (56%) 379 (58%)
Wait and see 345 (39%) 246 (37%)
Do nothing 37 (4%) 34 (5%)
Patient concern for long-term health as a
consequence of having COPD, n (%)
Not at all worried 38 (3%) 16 (2%)
Not particularly worried 112 (9%) 25 (3%)
Neither worried nor unworried 167 (14%) 94 (12%)
Somewhat worried 671 (55%) 358 (47%)
Extremely worried 236 (19%) 271 (35%)
Patient fear of premature death from COPD, n (%)
Not at all scared 171 (14%) 59 (8%)
Not particularly scared 536 (44%) 230 (30%)
Quite scared 368 (30%) 319 (41%)
Very scared 101 (8%) 134 (17%)
Fear of premature death from an
exacerbation (baseline: n=875 & 659), n (%)
Not at all scared 110 (13%) 47 (7%)
Not particularly scared 327 (37%) 176 (27%)
Quite scared 305 (35%) 267 (41%)
Very scared 104 (12%) 149 (23%)
MRC=Medical Research Council breathlessness scale; COPD=chronic obstructive
pulmonary disease.
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are not recruited into clinical trials, and because the pa-
tient definition of an exacerbation may not be the same
as that used in clinical trials), and suggest that the ‘real-
world’ experience of COPD patients is different from
that of patients in a research setting. The inclusion of
approximately twice as many patients with chronic bron-
chitis compared with patients with emphysema in our sur-
vey may contribute to the relatively high prevalence of
exacerbations and relative paucity of comorbidities in our
survey.Our survey cohort reported that recovery from exacer-
bations could be slow or incomplete, especially for MRC
3, 4 and 5 patients. Again, this supports data from clin-
ical studies that demonstrated incomplete recovery 35
days after exacerbation in approximately a quarter of pa-
tients [12,23]. The high levels of healthcare utilization
Figure 4 Frequency of exacerbations in the preceding 12 months.
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by other studies. In PERCEIVE, 89% of patients who had
experienced an exacerbation needed to see their doctor,
and 21% required hospital admission [7]. Exacerbations
generated a mean (standard deviation) of 5.1 (4.6) visits
to the doctor per patient per year [7].Figure 5 Response to an exacerbation.In a cohort of 128 patients with COPD, earlier treat-
ment of exacerbations was associated with faster recovery
(regression coefficient 0.42 days/day delay of treatment;
confidence interval, 0.19–0.65; p<0.001), and failure to re-
port exacerbations was associated with an increased risk
of emergency hospitalization (Spearman's rank correlation
Figure 6 Treatment-seeking triggers during an exacerbation.
Figure 7 Impact of COPD and exacerbations.
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in our survey took a ‘wait and see’ approach to exacerba-
tions, there is a clear need for better patient education that
stresses the importance of a rapid response to symptoms
of an exacerbation.
In our survey, exacerbations impacted everyday activ-
ities such as sleeping, walking and the ability to commit
to future events. For COPD patients of working age,
such as those in our cohort, there are additional con-
cerns. For example, a survey of 2,426 COPD patients
aged 45–68 years revealed that nearly one in five patients
was forced to retire prematurely because of their condi-
tion [8]. In addition, patients expressed concern about
their ability to maintain their lifestyle and plan for the fu-
ture [8]. Patients in our survey expressed similar concerns
about their future health, as well as fears of premature
death arising from COPD, especially as a result of an ex-
acerbation. Palliative care is an important component in
the treatment of COPD patients, particularly those with
severe disease [25], but access remains poor [26]. Current
guidelines recommend that clinicians initiate discussions
about end-of-life care with appropriate patients [4,27].
Conclusions
Our global survey – carried out almost a decade after
the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) published its first consensus report on the
diagnosis, management and prevention of COPD [28] –
has shown that exacerbations remain a major burden to
COPD patients and their families, and put a consider-
able demand on healthcare services. Furthermore, exac-
erbations may be more common in a ‘real-world’ COPD
population compared with those in clinical trials.
Our survey has also shown that there is a mismatch
between patient perceptions of COPD and the reality of
their frequent exacerbations, impaired quality of life and
fears for the future. In addition, a high proportion of pa-
tients were unaware of the importance of a rapid re-
sponse to exacerbations, which may be necessary to
achieve early and complete resolution of symptoms and
recovery of lung function.
By highlighting the fears and concerns of COPD pa-
tients, many of whom are of working age with financial
and familial responsibilities, the survey draws attention
to the need for better patient education regarding the se-
verity of the disease, the importance of prompt treat-
ment of exacerbations, and the treatment and lifestyle
options available.
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